Replies to post #1909 on Viropro, Inc. (VPRO)

[The Rainmaker]

Septembers news was talking about the exact same thing as today's deal. They are identical. 1/3 of $6.9 million in revenue or $2.3 million over three years from Spectrum

IDENTICAL: EVERYONE CAN SEE IT'S THE SAME DEAL

So far, Viropro has focused on the development of a biosimilar version of Rituximab and has already reached an agreement for the manufacturing and sale of this biosimilar with Intas Biopharmaceuticals. The company is in discussions with three other groups for agreements that would represent revenues USD 6.9 million.

===================================================================

Spectrum Pharmaceuticals Inc. (SPPI) signed a deal with Viropro Inc. (VPRO) to develop a biosimilar version of Swiss pharmaceutical giant Roche Holding AG's (RHHBY, ROG.VX) cancer drug rituximab